Overall survival by IDH2 mutant allele (R140 or R172) in patients with late-stage mutant-IDH2 relapsed or refractory acute myeloid leukemia treated with enasidenib or conventional care regimens in the phase 3 IDHENTIFY trial Meeting Abstract
| Authors: | De Botton, S.; Risueño, A.; Schuh, A. C.; Lowenberg, B.; Kim, H. J.; Vyas, P.; Wei, A. H.; Stein, E. M.; Dohner, H.; Fathi, A. T.; Dinardo, C. D.; Regueira, P. M.; Taningco, L.; Bluemmert, I.; Yu, X.; See, W. L.; Hasan, M. |
| Abstract Title: | Overall survival by IDH2 mutant allele (R140 or R172) in patients with late-stage mutant-IDH2 relapsed or refractory acute myeloid leukemia treated with enasidenib or conventional care regimens in the phase 3 IDHENTIFY trial |
| Meeting Title: | 2022 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 40 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2022 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2022-06-01 |
| Language: | English |
| ACCESSION: | WOS:000863680301906 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2022.40.16_suppl.7005 |
| Notes: | Meeting Abstract: 7005 -- This meeting was also held virtually -- Source: Wos |
